1025873-21-5

Basic information

• Product Name: 5,5-dimethyl-3-{2-oxo-3-[4-(4-trifluoromethoxy-phenoxy)-phenylsulfanyl]-propyl}-imidazolidine-2,4-dione
• Synonyms: 5,5-dimethyl-3-{2-oxo-3-[4-(4-trifluoromethoxy-phenoxy)-phenylsulfanyl]-propyl}-imidazolidine-2,4-dione
• CAS NO: 1025873-21-5
• Molecular Weight: 468.453
• Mol File: 1025873-21-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5,5-dimethyl-3-{2-oxo-3-[4-(4-trifluoromethoxy-phenoxy)-phenylsulfanyl]-propyl}-imidazolidine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5,5-dimethyl-3-{2-oxo-3-[4-(4-trifluoromethoxy-phenoxy)-phenylsulfanyl]-propyl}-imidazolidine-2,4-dione(1025873-21-5)
• EPA Substance Registry System: 5,5-dimethyl-3-{2-oxo-3-[4-(4-trifluoromethoxy-phenoxy)-phenylsulfanyl]-propyl}-imidazolidine-2,4-dione(1025873-21-5)

Safety Data

• Hazardous Substances Data: 1025873-21-5(Hazardous Substances Data)

Upstream product

• 361547-21-9 dithiocarbonic acid O-ethyl ester S-(4-(4-trifluoromethoxyphenoxy)phenyl) ester 
• 74030-44-7 1-nitro-4-(4-(trifluoromethoxy)phenoxy)benzene 
• 350-46-9 4-Fluoronitrobenzene 
• 828-27-3 4-Trifluoromethoxyphenol 
• 220616-31-9 3-(3-bromo-2-oxopropyl)-5,5-dimethylimidazolidine-2,4-dione 
• 220616-47-7 4-(4'-trifluoromethoxyphenoxy)-benzenethiol 

Relevant articles and documents

Phenoxyphenyl sulfone N-formylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors

A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1′ substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a.highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.